Point-of-care vs. lab-based covid-19 testing

Article tags In-vitro diagnosticsMolecular Diagnostics (MDx)Point-of-care testing (POCT)AsiaIVD GatewayMolecular Diagnostics (MDx)Point-of-care testing (POCT)

Covid-19 testing has emerged as a top priority for clinical laboratories and many IVD players. SARS-CoV-2 tests make up more than half of Asia-Pacific’s (APAC’s) total infectious disease diagnostics market. 

The use of different tests across APAC varies according to each country’s covid-19 strategy and local testing capacity.

• Molecular diagnostics (MDx): molecular testing is the predominant test method in APAC. MDx tests make up more than 85% of total covid-19 test volume in Singapore which has strong laboratory-based molecular testing capacity. 

• Immunoassays: Indonesia conducts a comparatively higher proportion of covid-19 testing using immunoassays. Mass testing in the country relied heavily on serological tests. In 2020, Indonesia’s immunoassay test volume per capita was three times as much as in China.

• Point-of-care (POC) diagnostics: India and Indonesia have a comparatively higher utilisation of POC diagnostics for covid-19 testing. In 2020, India’s POC test volume amounted to almost similar levels for laboratory-based testing—which include immunoassays and MDx tests carried out at central and molecular labs.

For more on the infectious diseases testing market, download the briefing paper on Infectious disease diagnostics in Asia-Pacific. 

Tue, 16th Nov 2021 Article tags In-vitro diagnosticsMolecular Diagnostics (MDx)Point-of-care testing (POCT)AsiaIVD GatewayMolecular Diagnostics (MDx)Point-of-care testing (POCT)